Dasatinib 100 Mg Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 100 mg, 20 mg
Reference Brands: Phyrago (USA)
Category:
Orphan Drugs
This medication is used to treat certain types of cancer (chronic myeloid leukemia-CML, acute lymphoblastic leukemia-ALL). It works by slowing or stopping the growth of cancer cells.
Dasatinib 100 mg Tablet is available in Tablets
and strengths such as 100 mg, 20 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Dasatinib 100 mg Tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Dasatinib 100 mg Tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Dasatinib, marketed under the brand name Sprycel among others, is a targeted therapy used to treat specific types of leukemia. It is primarily indicated for patients with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) who are Philadelphia chromosome-positive (Ph+). By inhibiting abnormal tyrosine kinase activity, dasatinib helps to control the growth and proliferation of cancerous cells, offering an effective treatment option for patients with these blood cancers.
This therapy works as a tyrosine kinase inhibitor, targeting BCR-ABL and other kinases involved in the signaling pathways that drive cancer progression. Dasatinib provides both first-line and later-line treatment options depending on the patient’s disease stage and previous therapies.
Dasatinib is available under the brand name Sprycel and various generics, manufactured in FDA-, EMA-, and MHRA-approved facilities for the USA, EU, and UK markets. Its use requires careful monitoring by healthcare professionals to manage potential side effects and ensure optimal outcomes.
By understanding the mechanism, indications, and administration of dasatinib, healthcare providers can deliver individualized treatment plans that improve patient outcomes and quality of life in leukemia management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing